Sun Pharma completes acquisition of Concert Pharmaceuticals

Sun Pharma has announced the completion of its acquisition of Concert Pharmaceuticals, headquartered in the United States. In January, the Mumbai-based firm agreed to buy Concert for USD 576 million. Sun Pharma said in a regulatory filing that it had completed the purchase of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata.

"We are thrilled to add deuruxolitinib, a late-stage, potentially best-in-class treatment for alopecia areata, to our expanding global dermatology portfolio and to extend our presence in the Boston biotech hub," Sun Pharma North America CEO Abhay Gandhi said. This acquisition, by combining Concert's talented team with Sun Pharma's global reach and commercial capabilities, represents a chance to bring deuruxolitinib to market globally and make a significant impact for alopecia areata patients worldwide, he added. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry.